Navigation Links
Cholesterol metabolism links early- and late-onset Alzheimer's disease
Date:10/4/2007

Oct. 4, 2007 -- Although the causes of Alzheimer's disease are not completely understood, amyloid-beta (A-beta) is widely considered a likely culprit the "sticky" protein clumps into plaques thought to harm brain cells.

But now researchers at Washington University School of Medicine in St. Louis have uncovered evidence strengthening the case for another potential cause of Alzheimer's. The finding also represents the first time scientists have found a connection between early- and late-onset Alzheimer's.

In a study published in the Oct. 4, 2007 issue of the journal Neuron, the scientists report that when A-beta is made, a small bit of protein is also released that can regulate cholesterol levels in the brain. The discovery adds weight to the less prominent theory that abnormal brain cholesterol metabolism plays a role in the mental decline seen in Alzheimer's patients.

"Our research links two major determinants for early- and late-onset Alzheimer's disease," says senior author Guojun Bu, Ph.D., professor of pediatrics and of cell biology and physiology. "And we've shown that the process that links them is implicated in brain cholesterol metabolism."

The report follows closely on another study reporting that statins, widely prescribed cholesterol-lowering drugs, could prevent certain neural changes that signal the progression of Alzheimer's disease. Additional earlier studies support the idea that statins could benefit Alzheimer's patients; however, other studies have found no such protective effect from statins.

"The studies of statins and Alzheimer's have generated quite a bit of controversy," Bu says. "Those that show positive effects from statins seem to suggest that high cholesterol could increase the risk of Alzheimer's disease. But other evidence contradicts this idea."

In fact, the brain needs a high level of cholesterol, according to Bu. "The brain represents only about 2 percent of your body weight, but actually has about 20 percent of your body's cholesterol," Bu says. "There is strong evidence that cholesterol is important for synaptic function and is an essential component of cell membranes in the brain, and I believe partial defects in the regulation of cholesterol metabolism in the brain likely contribute to the development of Alzheimer's."

In the current study, Bu and colleagues found an aspect of cholesterol transport and metabolism in the brain was a link between early- and late-onset Alzheimer's disease. Both forms of the disease result in similar brain lesions and have the same symptoms, including difficulties communicating, learning, thinking and reasoning, which suggests they share underlying mechanisms. But until now, no one has been able to identify such a mechanism.

Early-onset Alzheimer's can be traced to mutations in one of three genes, and the gene coding for A-beta's precursor, APP, is one of these. People with mutations in APP nearly always develop Alzheimer's disease, usually at a relatively young age.

The genetic origins of late-onset Alzheimer's, which accounts for 95 percent of cases, have proven harder to pin down. However, studies have shown that people who have a particular mutation in the gene for a cholesterol carrier called apolipoprotein E are far more likely to develop Alzheimer's in old age than those who don't have the mutation.

Bu and colleagues demonstrated that APP and apolipoprotein E have a molecular connection. When APP is cleaved by a specific enzyme in the brain, it releases A-beta plus a small protein fragment. The fragment then can regulate apolipoprotein E, which moves cholesterol in the brain from support cells to neurons.

Past research by others implies that neural synapses, the junctions that nerves use to send impulses and communicate, are particularly sensitive to cholesterol levels and that interfering with cholesterol transport and metabolism could cause loss of synapses and degeneration of nerves.

"Cholesterol metabolism in the brain is an understudied area, and our findings could inspire Alzheimer's researchers to look further into the role of the cholesterol pathway," Bu says. "Right now, research on Alzheimer's treatment focuses largely on reducing A-beta production or increasing its clearance from the brain. Our study suggests that there could be an alternate way to treat the disease, perhaps by modulating the function of apolipoprotein E and cholesterol in the brain."

Bu and his colleagues plan to screen for compounds that regulate the molecular components that they found to be involved in cholesterol metabolism. They hypothesize that such compounds could work to enhance the brain's cholesterol metabolism and alleviate Alzheimer's symptoms.


'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University in St. Louis
Source:Eurekalert

Related biology news :

1. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
2. Babys genes affect moms cholesterol levels
3. Cholesterol gets thumbs up for role in digit development
4. Nearly half of people who need cholesterol treatment dont get it
5. Gene transfer using mutant form of good cholesterol cuts vascular plaque and inflammation
6. New study finds chocolate chip cookies lower cholesterol
7. Primitive yeast yields secrets of human cholesterol and drug metabolism
8. Pistachios lower cholesterol, provide antioxidants
9. Opposing fat metabolism pathways triggered by a single gene
10. Attacks of King George IIIs madness linked to key metabolism molecule
11. Computational model simulates AZT metabolism in mitochondria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... Norwood, MA (PRWEB) , ... March 29, 2017 , ... ... year centered on patient-involved research, Colpitts Clinical Trial Travel has announced that it will ... of Direct Travel, was among the first in the United States and Europe to ...
(Date:3/29/2017)... SAN DIEGO and NEWARK, Del. ... Inc. , a privately-held regenerative medicine company, and ... global materials science company, today announced a collaborative research ... develop novel implantable cell therapy delivery device technologies that ... more than a decade, ViaCyte has been developing innovative ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Association for the Advancement of Science (AAAS), the world's largest general scientific ... enhance its high-impact scholarly collection across its cross-platform reference management system. , ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation ... over two years to develop a suite of BioGel™ biopolymer materials for hygiene ...
Breaking Biology Technology: